Sepsis and its related encephalopathy
Conditions
Interventions
Healthy Control Group:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: Healthy Control Group; 1. Aged 18–85 years; 2. The participant or his/her legally authorised representative voluntarily agrees to participate in this study and signs the informed consent form; 3. Physical examination or medical history indicates no definite infectious disease; 4. No previous history of definite central nervous system disease, such as stroke, epilepsy, encephalitis, or sequelae of traumatic brain injury; 5. No previous history of severe psychiatric disorder; 6. No previous history of severe chronic systemic disease, including but not limited to severe heart failure, severe chronic pulmonary disease, or severe hepatic or renal dysfunction; 7. No previous history of definite autoimmune disease or malignant tumour. Sepsis Patient Group; 1. Meets the latest diagnostic criteria for sepsis (Sepsis-3 criteria), defined as an acute increase in SOFA score of >=2 points in the presence of suspected or confirmed infection; 2. Aged 18–85 years; 3. The participant or his/her legally authorised representative voluntarily agrees to participate in this study and signs the informed consent form.
Exclusion criteria
Exclusion criteria: Healthy Control Group; 1. Presence of acute infection or a recent history of infection within the past 1 month; 2. Previous or current definite central nervous system disease or severe psychiatric disorder; 3. Presence of malignant tumour, severe hepatic or renal dysfunction, or other severe chronic systemic disease; 4. Long-term use of immunosuppressive agents, glucocorticoids, or biological agents; 5. Pregnancy or lactation; 6. Any other condition considered by the investigator to be unsuitable for inclusion in this study. Sepsis Patient Group; 1. A previous history of definite central nervous system disease, such as stroke, epilepsy, encephalitis, or sequelae of traumatic brain injury, or a history of severe psychiatric disorder; 2. Presence of malignant tumour, severe hepatic or renal dysfunction, or long-term use of high-dose glucocorticoids; 3. Presence of severe chronic systemic disease, such as end-stage heart failure or end-stage pulmonary disease, or definite autoimmune disease; 4. Presence of severe chronic systemic disease, such as end-stage heart failure or end-stage pulmonary disease, or definite autoimmune disease; 5. Current use of immunosuppressive agents or biological agents; 6. Pregnancy or lactation; 7. Any other condition considered by the investigator to be unsuitable for inclusion in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative FLVCR1 mRNA expression in peripheral blood mononuclear cells; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine laboratory tests: White blood cell count (WBC), hemoglobin (Hb), platelet count (PLT), C-reactive protein (CRP), serum albumin, AST, ALT, creatinine (Cr), estimated glomerular filtration rate;Assessment of consciousness, delirium, and sepsis-associated encephalopathy; | — |
Countries
China
Contacts
Public ContactJunlu Wang
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed